NICE recommends Roche's MabThera for second time
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has once again recommended Roche's anticancer MabThera (rituximab) as a first-line maintenance treatment for patients with follicular non-Hodgkin's lymphoma who have responded to first-line induction therapy with rituximab together with chemotherapy, in its latest draft guidance.